TABLE 1

Univariate analysis of factors associated with all-cause 28-day mortality of 205 patients with carbapenemase-producing K. pneumoniae bloodstream infections

VariableResult for patients who:P
Survived (n = 123)Died (n = 82)
Age, mean yr (SD)60.2 (18.9)66.4 (14.5)0.008
Gender, no. (%)0.018
    Male79 (66.9)39 (33.1)
    Female44 (50.6)43 (49.4)
Acquisition of infection, no. (%)0.584
    Health care associated8 (53.3)7 (46.7)
    Hospital acquired115 (60.5)75 (39.5)
Hospital, no. (%)1.00
    A102 (60.0)68 (40.0)
    B21 (60.0)14 (40.0)
Ward at onset of BSI, no. (%)0.687
    Non-ICU52 (58.4)37 (41.6)
    ICU71 (61.2)45 (38.8)
Charlson comorbidity index, median (IQR)1 (0–2)2 (1–4)0.001
Severity of underlying disease, no. (%)a<0.001
    Nonfatal87 (79.8)22 (20.2)
    Ultimately fatal21 (39.6)32 (60.4)
    Rapidly fatal15 (34.9)28 (65.1)
Neutropenia, no. (%)0.030
    No117 (62.2)71 (37.8)
    Yes6 (35.3)11 (64.7)
Severity of sepsis, no. (%)<0.001
    Sepsis96 (69.6)42 (30.4)
    Severe sepsis12 (42.9)16 (57.1)
    Septic shock15 (38.5)24 (61.5)
Polymicrobial BSI, no. (%)0.049
    No95 (64.2)53 (35.8)
    Yes28 (49.1)29 (50.9)
Source of BSI, no. (%)0.844
    Non-urinary tract112 (60.2)74 (39.8)
    Urinary tract11 (57.9)8 (42.1)
Carbapenemase type(s), no. (%)0.090
    VIM30 (71.4)12 (28.6)
    KPC/KPC + VIM93 (57.1)70 (42.9)
ST, no. (%)0.269
    ST25848 (55.8)38 (44.2)
    Other52 (64.2)29 (35.8)
Time to initiation of at least 1 active drug, no. (%)
    >48 h50 (53.2)44 (46.8)0.086
    ≤48 h73 (65.8)38 (34.2)
Empirical treatment, no. (%)0.250
    No active drug50 (55.5)40 (44.5)
    At least 1 active drug73 (63.5)42 (36.5)
Definitive treatment, no. (%)b0.018
    Monotherapy40 (55.6)32 (44.4)
    Combination therapy75 (72.8)28 (27.2)
  • a As determined according to the McCabe and Jackson classification (21, 22).

  • b Patients who received at least one active drug for more than 48 h.